RxDoctor Payments DataLook up a doctor →

Ronald Oudiz, MD

Cardiovascular Disease · Torrance, CANPI 1316957228

Payments from drug & device makers

$2,587,503in general payments, 2019–2025

Across 961 payments — averaging $2692.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.6M
  • United Therapeutics Corporation$410K
  • Janssen Research & Development, LLC$282K
  • Actelion Pharmaceuticals US, Inc.$203K
  • Insmed, Inc.$47K
  • Actelion Pharmaceuticals, Ltd$13K
  • plus $29K from 28 others
$6,826in research payments, 2019–2025

Across 20 payments — averaging $341.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$6K
  • Medtronic$1K

What the payments were for

  • Consulting fees$150,92624%
  • Speaking & faculty fees$373,49461%
  • Travel & lodging$75,90612%
  • Food & beverage$16,5893%
  • Education$4030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,587,503 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$11,784
Medicare patients
26
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag113$2,404,066
Ambrisentan136$697,772
WinrevairSotatercept-Csrk49$680,689
Orenitram ErTreprostinil Diolamine25$625,784
OpsumitMacitentan49$608,488
Tyvaso DpiTreprostinil21$514,593
OpsynviMacitentan/Tadalafil15$271,263
LetairisAmbrisentan13$148,455
Tadalafil108$93,299
Bosentan12$26,653
Sildenafil Citrate48$17,615
Potassium Chloride11$455
Digoxin11$375
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$173
Omeprazole13$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi, Bosentan$202,766$3,310,469189 claims
MerckWinrevair$1,603,863$680,68949 claims
GileadLetairis$5,371$148,45513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →